Sara Mangsbo, Senior Lecturer at the Department of Pharmacy and Chief Innovation Officer at Ultimovacs, receives the BiotechBuilders Award 2022.
The award is given each year to an entrepreneur who has created unique opportunities which brings the Swedish life science industry forward. The organization behind the award, BiotechBuilders, states in its motivation that Sara Mangsbo “for more than a decade has translated her research into immunological methodology and precision medicine immunological treatment of cancer into numerous patents, innovations and life science companies.”
Sara Mangsbo is co-founder of Immuneed AB, VivoLogica AB and Strike Pharma AB, as well as Head of innovation at Ultimovacs ASA/AB and Head of research at Strike Pharma AB.
Read more: Interview with Sara Mangsbo: A multi-talented scientist and entrepreneur
“It is very inspiring for me to work in the borderlands between industry and academia. It provides new networks and increases my understanding of companies’ conditions, while I, together with my research team, am able to take on unanswered scientific questions that can create the basis for new innovations and companies. Receiving the BiotechBuilders Award gives me valuable energy in research, education and collaboration and contributes to consolidating Uppsala’s place on the Swedish Life Science map. This is truly a city where interaction between industry and academia is made possible and where we work together for innovation and job creation within Life Science and Biopharmaceuticals,” says Sara Mangsbo to Magnus Alsne, Uppsala Univeristy.
Sara Mangsbo received the BiotechBuilders Award 2022 at this year’s forum – Intelligence Of The Future – which took place 29 August at Stora Frösunda farm.
Photo of Sara Mangsbo: Mikael Wallerstedt